This shows the main results of the EMBARK trial, comparing Metatasis Free Survival and PSA Recurrence Free Survival for three groups: Enzalutamide only, Lupron only, or combined Enzalutamide + Lupron.
The best survivals were for the combination of Enzalutamide + Lupron.
Enzalutamide is a 2nd generation Anti-Androgen, and Lupron is an anti-testosterone agent.
From the study..... " The safety profile of enzalutamide was consistent with that shown in previous clinical studies, with no apparent detrimental effect on quality of life." If adding enzalutamide does not add significantly to QOL problems, that is one thing. If the combo actually has a more concerning QOL profile, then, to me, The enzalutamide monotherapy provides just slightly less desirable results than the combo, and I would be tempted to go that route?
Thanks for everything you are providing to folks here!!!
Good question. I think "Metatasis-Free" means free from Mets at the beginning of the trial.
The summary of the paper says: "In this phase 3 trial, we enrolled patients with prostate cancer who had high-risk biochemical recurrence with a prostate-specific antigen doubling time of 9 months or less." It doesn't say, but I'm assuming that there are no mets at the beginning. But, the short PSA doubling time (DT) means that they have active prostate cancer growing.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.